Our Company

1-4 of 4

The impact of California’s prescription drug cost-sharing cap27 March 2018 - By Gabriela Dieguez and Bruce S. Pyenson and Andrew Bochner - Article

This report analyzes the impact of the per-prescription cost-sharing cap for non-catastrophic plans on projected prescription drug spending across the California individual and small group markets.

Open vs. minimally invasive hysterectomy: Commercially insured costs and readmissions22 August 2016 - By Warner Huh and Andrew Bochner and Kathryn V. Fitch - Article

This paper analyzes commercial payer differences in the average costs and readmission rates between inpatient open hysterectomies and three types of outpatient hysterectomies: laparoscopic, laparoscopic assisted, and vaginal.

Cost differences between open and minimally invasive surgery06 August 2016 - By Andrew Bochner and Kathryn V. Fitch and Tyler Engel - Article

This study analyzes the difference in payer costs between minimally invasive surgery and open surgery in a commercial population for four commonly performed elective surgical procedures.

An actuarial approach to the incremental cost of Hepatitis C in the absence of curative treatments24 September 2015 - By Andrew Bochner and Bruce S. Pyenson and Ryan Cannon - Article

HCV is the leading cause of both liver-related deaths and liver transplants in the United States. The high cost of new antiviral medicines has sparked debate over the cost of treating HCV, and some payers are seeking ways to minimize their spending on these medicines.


  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman